Curium and PDRadiopharma are partnering to advance clinical development and commercialization of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T theranostics in Japan.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.